• LevelJump Healthcare Corp. (JUMP) has announced a non-brokered private placement to raise gross proceeds of up to $10,000,000
  • The company will issue up to 10,000,000 units at $1.00 per unit
  • Each unit will consist of one common share and one Class A Series 1 preferred share
  • The offering is expected to close in November 2022
  • Leveljump Healthcare is a healthcare company
  • LevelJump Healthcare Corp. (JUMP) is unchanged on the day, trading at C$0.085 per share at 1:30 pm ET

LevelJump Healthcare Corp. (JUMP) has announced a non-brokered private placement to raise gross proceeds of up to $10,000,000.

The company will issue up to 10,000,000 units at $1.00 per unit. Each unit will consist of one common share and one 8 per cent redeemable convertible Class A Series 1 preferred share.

Each preferred share is non-voting and carries a cumulative annual dividend of 8 per cent, payable quarterly. 

The offering is expected to close in November 2022 and is conditional upon receipt of all required regulatory approvals.

All securities issued will be subject to a statutory four-month hold period.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

LevelJump Healthcare Corp. (JUMP) is unchanged on the day, trading at C$0.085 per share at 1:30 pm ET.


More From The Market Online

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.

PharmaTher evaluating 3D printing for personalized peptide medicines

PharmaTher is out to evaluate its GMP-ready 3D printing platform for producing personalized peptide medicines with customized doses.

Why biotech is outpacing the AI slump: 3 stocks to watch

The biotech sector is outperforming the broader market, shining a light on stocks best-positioned to address unmet patient needs.